The signing of PAHPRA was huge news, that was ignored by the press.
Delivery was also big news. It seems to me that the first 300,000 plus this 190,000 is 490,000 courses of 2 million courses, as in the press release. Or is it 190,000 of 1.7 million, as in the contract. 5000,000 courses triggers payment.
I want in on any company "overcharging" the government, even if it is deferred revenue. Arestvyr should be branded as an "all"pox antiviral.
Monkeypox virus (MPXV) was isolated in 1958 from lesions on laboratory monkeys imported to Denmark from Singapore and was identified as a member of the Orthopoxvirus genus of the family Poxviridae (46). Human cases of monkeypox were first reported in the early 1970s in Africa, although it is likely they occurred earlier but were misdiagnosed as smallpox prior to the eradication of that disease (reviewed by Parker et al. ). MPXV is endemic in rain-forested regions of Africa and causes a disease that clinically resembles smallpox but with reduced morbidity and mortality. Two subgroups of MPXV with distinct genetic, clinical, and epidemiological characteristics have been described (6, 25, 47). Central African isolates can cause severe disease; they have limited human-to-human transmission and can cause up to 10% case fatality (4, 24, 33). In contrast, West African isolates are less virulent, with no reported human-to-human transmission. Sequencing studies have suggested several mutations that might account for the differences in virulence of MPXV strains.
The major reservoir of MPXV, in spite of its name, is believed to be rodents, particularly squirrels (10, 21, 36). The year 2003 outbreak of human monkeypox in the midwestern United States was caused by a West African strain carried by infected rodents imported from Ghana, highlighting the ease of transport and spread of MPXV to regions of the globe where the virus is not endemic (35). The susceptibility of North American rodents to MPXV highlights the potential of geographic spread of this virus. Moreover, MPXV like variola virus (VARV), the causative agent of smallpox, is a potential bioterrorist agent. Due to the cessation of routine vaccination more than 3 decades ago, much of the population is now at risk (17), and recent surveys have shown an increase in incidence of monkeypox in the Democratic Republic of Congo (37).